Unlike generics, biosimilars are similar, but not equivalent, to the reference biological medicinal product. Therefore, if a patient experiences an adverse event, or a loss of efficacy, when transitioned to a biosimilar, the distribution of medical liability will be different from the case of both the originator and generics. Moreover, the case of naïve patients is different from that of non-naïve patients. In the case of naïve patients, physicians make their choice from a range of medicinal products that pose the same risk, since it is not possible to know with any certainty the patients' response to each therapeutic option until they have taken the drug. If physicians, instead, switch to a biosimilar for a patient already in treatment with the originator, they are switching from an option where the individual response is known, to an option where it is unknown. Given the evolving framework of biosimilar legislation, sharing choices with patients and obtaining their informed consent when switching to a biosimilar could represent an effective approach on the part of the prescribing physician. Moreover, a supranational database containing real-life data about patients in treatment with biological medicines, including information on the actual biological medicinal products administered, could complement the data obtained from clinical studies.

Biosimilar switching and related medical liability / P. Rocco, S. Selletti, P. Minghetti. - In: JOURNAL OF FORENSIC AND LEGAL MEDICINE. - ISSN 1752-928X. - 55(2018 Apr), pp. 93-94. [10.1016/j.jflm.2018.02.018]

Biosimilar switching and related medical liability

P. Rocco
Primo
;
P. Minghetti
Ultimo
2018

Abstract

Unlike generics, biosimilars are similar, but not equivalent, to the reference biological medicinal product. Therefore, if a patient experiences an adverse event, or a loss of efficacy, when transitioned to a biosimilar, the distribution of medical liability will be different from the case of both the originator and generics. Moreover, the case of naïve patients is different from that of non-naïve patients. In the case of naïve patients, physicians make their choice from a range of medicinal products that pose the same risk, since it is not possible to know with any certainty the patients' response to each therapeutic option until they have taken the drug. If physicians, instead, switch to a biosimilar for a patient already in treatment with the originator, they are switching from an option where the individual response is known, to an option where it is unknown. Given the evolving framework of biosimilar legislation, sharing choices with patients and obtaining their informed consent when switching to a biosimilar could represent an effective approach on the part of the prescribing physician. Moreover, a supranational database containing real-life data about patients in treatment with biological medicines, including information on the actual biological medicinal products administered, could complement the data obtained from clinical studies.
biosimilars, Interchangeability; substitution; non-naïve patients; informed consent; medical liability
Settore CHIM/09 - Farmaceutico Tecnologico Applicativo
apr-2018
Article (author)
File in questo prodotto:
File Dimensione Formato  
JournForensicLegalMed_BiosimilarSwitching_2017.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 118.16 kB
Formato Adobe PDF
118.16 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Rocco_post_print.pdf

accesso aperto

Descrizione: Post-print
Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 158 kB
Formato Adobe PDF
158 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/553459
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 10
social impact